Studies analyzing cancer genomics have found that high expression of IDO1 indicates poor prognosis in colorectal cancer, but in certain hormone-related cancers such as breast cancer and ovarian cancer, higher IDO1 expression is associated with significantly prolonged survival and better prognosis compared to lower IDO1 expression levels. This evidence concerns the gene IDO1 and breast carcinoma.